Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -0.28% | 60.92 | 0.0% | $915.58m | |
| NVAX | Novavax, Inc. | 1.53% | 106.16 | 102.0% | $838.44m | |
| AMGN | Amgen, Inc. | -1.21% | 253.15 | 1.3% | $733.54m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.13% | 654.50 | 2.5% | $702.41m | |
| GILD | Gilead Sciences, Inc. | -0.13% | 76.32 | 1.0% | $675.67m | |
| BIIB | Biogen, Inc. | 7.70% | 289.00 | 1.6% | $617.99m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.31% | 300.00 | 1.9% | $524.61m | |
| ILMN | Illumina, Inc. | -1.92% | 372.12 | 3.5% | $297.26m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.98% | 112.46 | 2.0% | $230.21m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.16% | 127.77 | 4.3% | $212.31m | |
| SGEN | Seattle Genetics, Inc. | 3.34% | 176.14 | 6.1% | $207.80m | |
| SRNE | Sorrento Therapeutics, Inc. | 0.27% | 7.40 | 1.8% | $195.70m | |
| IMMU | Immunomedics, Inc. | 1.30% | 41.16 | 11.0% | $178.10m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.25% | 163.89 | 13.9% | $167.23m | |
| INCY | Incyte Corp. | 0.80% | 108.65 | 2.5% | $166.01m |
Company Profile
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.